What's Happening?
C2N Diagnostics, a U.S.-based specialty diagnostics company, has partnered with SouthGenetics to broaden access to its Precivity® blood tests for Alzheimer’s disease assessment in Latin America and the
Caribbean. This collaboration aims to support earlier and more accessible Alzheimer’s disease assessment in regions facing aging populations, limited dementia-specialist capacity, and constrained PET imaging infrastructure. The partnership will initially focus on countries such as Argentina, Chile, Colombia, Dominican Republic, Ecuador, Jamaica, Mexico, Uruguay, and Venezuela, with plans to evaluate additional countries. The Precivity® tests are designed to detect amyloid plaques in the brain, a pathological hallmark of Alzheimer’s disease, aiding healthcare professionals in medical management and treatment decisions.
Why It's Important?
The collaboration between C2N Diagnostics and SouthGenetics is significant as it addresses the growing need for scalable diagnostic solutions for Alzheimer’s disease in Latin America and the Caribbean. These regions are experiencing increasing aging populations and limited access to dementia specialists and advanced diagnostic infrastructure. The partnership aims to bridge the diagnostic divide by making advanced diagnostics accessible through reliable logistics, medical education, and country-specific execution. This initiative is crucial as recent regulatory approvals of disease-modifying therapies for Alzheimer’s disease in parts of Latin America are increasing demand for accurate, accessible tools to support clinical evaluation and patient-care pathways.
What's Next?
SouthGenetics will support regional implementation through its established commercial, medical, and logistics network across Latin America and the Caribbean. The company will work to facilitate physician awareness, country-specific activation, sample logistics, and access pathways for appropriate patients undergoing evaluation for cognitive impairment or dementia. Precivity® tests are available only through qualified healthcare professionals. The partnership builds on C2N’s prior experience supporting Alzheimer’s disease early initiatives in Latin America and other global settings, highlighting the potential role of scalable blood biomarkers in regions where access to dementia specialists and amyloid PET imaging may be limited.
